Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Marcus

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Leukemia Research|May 3, 2014
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphomaVictor Noriega, Harpreet Kaur, Stephen Devereux, et al.
Haematologica|May 3, 2020
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphomaAnton Hagenbeek, Houchingue Eghbali, Silvio Monfardini, et al.
British Journal of Clinical Pharmacology|March 14, 2019
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapyCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Understanding DP receptor antagonism using a CoMSIA approachLan Mu, Joacy Aguiar, Ali Ardati, et al.
Medicine and Science in Sports and Exercise|May 17, 2003
Disordered eating, menstrual irregularity, and bone mineral density in female runnersKristin L Cobb, Laura K Bachrach, Gail Greendale, et al.
Contemporary Clinical Trials|August 9, 2005
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older menEric Orwoll, Janet Babich Blank, Elizabeth Barrett-Connor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2013
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndromeVictoria T Potter, Pramila Krishnamurthy, Linda D Barber, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Leukemia Research|May 3, 2014
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphomaVictor Noriega, Harpreet Kaur, Stephen Devereux, et al.
Haematologica|May 3, 2020
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphomaAnton Hagenbeek, Houchingue Eghbali, Silvio Monfardini, et al.
British Journal of Clinical Pharmacology|March 14, 2019
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapyCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Understanding DP receptor antagonism using a CoMSIA approachLan Mu, Joacy Aguiar, Ali Ardati, et al.
Medicine and Science in Sports and Exercise|May 17, 2003
Disordered eating, menstrual irregularity, and bone mineral density in female runnersKristin L Cobb, Laura K Bachrach, Gail Greendale, et al.
Contemporary Clinical Trials|August 9, 2005
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older menEric Orwoll, Janet Babich Blank, Elizabeth Barrett-Connor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2013
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndromeVictoria T Potter, Pramila Krishnamurthy, Linda D Barber, et al.
Pageof 10